These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

363 related items for PubMed ID: 3926587

  • 21. Toxicological implications of drug metabolism.
    Welch RM.
    Pharmacol Rev; 1978 Dec; 30(4):457-67. PubMed ID: 392540
    [No Abstract] [Full Text] [Related]

  • 22. [Genotyping for drug metabolism capacity can give valuable clinical information].
    Ingelman-Sundberg M, Johansson I, Dahl ML, Bertilsson L, Yue QY, Sjöqvist F.
    Lakartidningen; 1992 May 06; 89(19):1675-8. PubMed ID: 1349665
    [Abstract] [Full Text] [Related]

  • 23. Genetic factors in hepatic drug oxidation.
    Kalow W, Inaba T.
    Prog Liver Dis; 1976 May 06; 5():246-58. PubMed ID: 775542
    [No Abstract] [Full Text] [Related]

  • 24. [Stability and/or variability of the expression of genetic polymorphism of hydroxylation and acetylation in patients with various pathologies and under various treatments].
    Bechtel P, Joanne C, Bechtel Y, Grandmottet M, Jounet JM.
    Ann Biol Clin (Paris); 1986 May 06; 44(4):361-7. PubMed ID: 3538951
    [Abstract] [Full Text] [Related]

  • 25. Cytochrome P450: genetic polymorphism and drug interactions.
    Belpaire FM, Bogaert MG.
    Acta Clin Belg; 1996 May 06; 51(4):254-60. PubMed ID: 8858891
    [Abstract] [Full Text] [Related]

  • 26. [Clinically significant inherited differences in the mode of action of drugs].
    Meyer UA, Meier PJ.
    Schweiz Med Wochenschr; 1982 May 08; 112(19):666-9. PubMed ID: 7100864
    [Abstract] [Full Text] [Related]

  • 27. Genetically determined polymorphisms in drug oxidation.
    Jacqz E, Hall SD, Branch RA.
    Hepatology; 1986 May 08; 6(5):1020-32. PubMed ID: 3758933
    [No Abstract] [Full Text] [Related]

  • 28. Determination of carcinogenic arylamine N-oxidation phenotype in humans by analysis of caffeine urinary metabolites.
    Kadlubar FF, Talaska G, Butler MA, Teitel CH, Massengill JP, Lang NP.
    Prog Clin Biol Res; 1990 May 08; 340B():107-14. PubMed ID: 2392442
    [No Abstract] [Full Text] [Related]

  • 29. Clinical implications of genetic polymorphisms and drug interactions mediated by cytochrome P-450 enzymes.
    Touw DJ.
    Drug Metabol Drug Interact; 1997 May 08; 14(2):55-82. PubMed ID: 9893738
    [Abstract] [Full Text] [Related]

  • 30. Adaptive responses of the liver to foreign compounds, with special reference to microsomal drug-matabolizing enzymes.
    Wada O, Yano Y.
    Rev Environ Health; 1974 May 08; 1(4):261-82. PubMed ID: 4617260
    [No Abstract] [Full Text] [Related]

  • 31. [Individual variations in the oxidative metabolism of drugs. Significance of monogenic polymorphism].
    Brøsen K.
    Ugeskr Laeger; 1984 Mar 26; 146(13):955-9. PubMed ID: 6719598
    [No Abstract] [Full Text] [Related]

  • 32. [Genetic polymorphism of acetylation and hydroxylation in the Briton population].
    Bressollette L, Berthou F, Riche C, Mottier D, Floch HH.
    Therapie; 1990 Mar 26; 45(2):99-103. PubMed ID: 2353336
    [Abstract] [Full Text] [Related]

  • 33. Biochemical individuality and its implications for drug and carcinogen metabolism: recent insights from acetyltransferase and cytochrome P4501A2 phenotyping and genotyping in humans.
    Kadlubar FF.
    Drug Metab Rev; 1994 Mar 26; 26(1-2):37-46. PubMed ID: 8082575
    [No Abstract] [Full Text] [Related]

  • 34. [Cytochrome P-450: the effect of drugs and poisons].
    Chekman IS, Grinevich AI.
    Farmakol Toksikol; 1984 Mar 26; 47(1):119-23. PubMed ID: 6705899
    [No Abstract] [Full Text] [Related]

  • 35. Polymorphism of human cytochrome P450 enzymes and its clinical impact.
    Zhou SF, Liu JP, Chowbay B.
    Drug Metab Rev; 2009 Mar 26; 41(2):89-295. PubMed ID: 19514967
    [Abstract] [Full Text] [Related]

  • 36. Renal drug metabolism.
    Lohr JW, Willsky GR, Acara MA.
    Pharmacol Rev; 1998 Mar 26; 50(1):107-41. PubMed ID: 9549760
    [No Abstract] [Full Text] [Related]

  • 37. Polymorphisms of oxidation at carbon centers of drugs and their clinical significance.
    Idle JR, Smith RL.
    Drug Metab Rev; 1979 Mar 26; 9(2):301-17. PubMed ID: 158499
    [No Abstract] [Full Text] [Related]

  • 38. The genetic control of drug oxidation in the liver.
    Dayer P, Balant L, Fabre J.
    Int J Clin Pharmacol Res; 1983 Mar 26; 3(6):421-5. PubMed ID: 6147316
    [Abstract] [Full Text] [Related]

  • 39. Genetic polymorphisms of drug metabolism.
    Meyer UA.
    Fundam Clin Pharmacol; 1990 Mar 26; 4(6):595-615. PubMed ID: 1982880
    [Abstract] [Full Text] [Related]

  • 40. [What do we know about the drug metabolism?].
    Pelkonen O, Raunio H.
    Duodecim; 1998 Mar 26; 114(10):971-7. PubMed ID: 11524785
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 19.